Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

715
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
715
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

770
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
770
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

673
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
673
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

537
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
537
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

349
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
349
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

336
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
336

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

[Low phospholipidassociated cholelithiasis syndrome].

La Revue du praticien·2026
Same author

Cholestatic biomarkers and symptoms in primary sclerosing cholangitis: a post-hoc analysis of the DILSTENT.

Scandinavian journal of gastroenterology·2026
Same author

RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis.

Science advances·2025
Same author

Epidemiology, comorbidities, treatments and outcomes of autoimmune liver diseases: A French nationwide study.

JHEP reports : innovation in hepatology·2025
Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025

Related Experiment Video

Updated: Dec 11, 2025

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

231

Liver and inflammatory bowel disease.

S Nahon1, J-F Cadranel, Olivier Chazouilleres

  • 1Service d'hépatogastroentérologie, centre hospitalier Le Raincy-Montfermeil, 10, avenue du Général-Leclerc, 93370 Montfermeil, France. snahon@club-internet.fr

Gastroenterologie Clinique Et Biologique
|April 28, 2009
PubMed
Summary

Inflammatory bowel disease (IBD) patients face unique liver complications, including drug-induced liver injury and nodular regenerative hyperplasia. Regular monitoring for early signs of liver issues is crucial for IBD patients.

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.0K

Related Experiment Videos

Last Updated: Dec 11, 2025

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

231
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.0K

Area of Science:

  • Gastroenterology and Hepatology
  • Clinical Pharmacology

Background:

  • Liver disease is uncommon in inflammatory bowel disease (IBD) patients.
  • Primary sclerosing cholangitis is more frequently seen in IBD patients than IBD in primary sclerosing cholangitis patients.
  • IBD management involves medications that can cause rare but serious liver issues.

Purpose of the Study:

  • To review the spectrum of liver diseases associated with inflammatory bowel disease.
  • To highlight drug-induced hepatic manifestations in IBD patients.
  • To emphasize the importance of early detection and monitoring of liver complications.

Main Methods:

  • Literature review of studies on liver disease in IBD.
  • Analysis of drug-induced liver injury in IBD patients.
  • Discussion of specific liver conditions like primary sclerosing cholangitis, nodular regenerative hyperplasia, and methotrexate-induced fibrosis.

Main Results:

  • Primary sclerosing cholangitis is the most common liver manifestation in IBD.
  • Purine analogues are linked to nodular regenerative hyperplasia, requiring monitoring for elevated alkaline phosphatase or low platelets.
  • Methotrexate-induced fibrosis is rare, but monitoring for fibrosis is advised.
  • Hepatitis B reactivation risk necessitates screening before infliximab use.

Conclusions:

  • IBD patients require vigilant monitoring for liver complications, including drug-induced injuries.
  • Early detection of liver issues like nodular regenerative hyperplasia and fibrosis is vital for prognosis.
  • Proactive screening for viral hepatitis and appropriate preventive treatment are essential for IBD patients undergoing specific therapies.